Amylyx Pharmaceuticals, Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $13.70 |
| Prev. Close | $13.58 |
| EPS | 0.01 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $956.05M |
| PE Ratio | 1,416.00 |
| low | high | |
|---|---|---|
| Day Range | 13.44 | 14.37 |
| 52 Week Range | 11.82 | 41.93 |
| Ratios | |
|---|---|
| P/B Ratio | 16.40 |
| Revenue | $294.22M |
| Operating M. % | 18.23% |
| Earnings | $1.83M |
| Earnings Growth % | 29,666.09% |
| EBITDA Margin % | -2.30% |
| ROE % | 0.65% |
| EPS | 0.01 |
Score Breakdown
All Score (61 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| AMLX | Market | |
|---|---|---|
| Value | 44 | 42 |
| Quality | 70 | 46 |
| Ownership | 72 | 39 |
| Growth | 40 | 44 |
| Dividends | - | 32 |
All Score (61 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joshua B. Cohen
- Headquarters
- Cambridge
- Employees
- 338
Keep an eye on Amylyx Pharmaceuticals, Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.